HUP0204177A2 - N-(Alkoxi-alkil)-N,N-dialkil-aminszármazékok vagy sóik és ezeket tartalmazó szerek neurodegeneratív betegségek kezelésére - Google Patents

N-(Alkoxi-alkil)-N,N-dialkil-aminszármazékok vagy sóik és ezeket tartalmazó szerek neurodegeneratív betegségek kezelésére

Info

Publication number
HUP0204177A2
HUP0204177A2 HU0204177A HUP0204177A HUP0204177A2 HU P0204177 A2 HUP0204177 A2 HU P0204177A2 HU 0204177 A HU0204177 A HU 0204177A HU P0204177 A HUP0204177 A HU P0204177A HU P0204177 A2 HUP0204177 A2 HU P0204177A2
Authority
HU
Hungary
Prior art keywords
alkoxyalkyl
salts
remedies
same
diseases containing
Prior art date
Application number
HU0204177A
Other languages
English (en)
Inventor
Noboru Iwakami
Massaya Nakagawa
Satoshi Ono
Akihito Saito
Sumie Yamaguchi
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of HUP0204177A2 publication Critical patent/HUP0204177A2/hu
Publication of HUP0204177A3 publication Critical patent/HUP0204177A3/hu
Publication of HU229250B1 publication Critical patent/HU229250B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

A találmány tárgyát az általános képletű N-(alkoxi-alkil)-N,N-dialkil-amin-származékok - ahol R1 és R2 lehet hidrogénatom, halogénatom,adott esetben szubsztituált alkil-, aril-, aralkil-, alkoxi-, aril-oxi-, alkil-tio-, aril-tio-, alkenil-, alkenil-oxi-, amino-,alkilszulfonil-, arilszulfonil-, karbamoil- vagy heterociklikuscsoport, adott esetben védett amino-, hidroxi- vagy karboxicsoport,nitro- vagy oxocsoport; R3 és R4 adott esetben szubsztituált alkil-,cikloalkil- vagy aralkilcsoport; R5', R6', R7' és R8' hidrogénatomvagy alkilcsoport; a D gyűrű 5- vagy 6-tagú heterociklikus gyűrű vagyszénhidrogéngyűrű; m = 1 és 5 közötti egész szám; és n = 1 és 6közötti egész szám - vagy sóik képezik, amelyek antihipoxiás, idegvédővagy idegregenerálódást elősegítő hatásúak, és neurodegeneratívbetegségek kezelésére alkalmazhatók. Ó
HU0204177A 1999-06-11 2000-06-09 N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same HU229250B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16587999 1999-06-11
PCT/JP2000/003748 WO2000076957A1 (fr) 1999-06-11 2000-06-09 Derives de n-alkoxyalkyl, n-dialkylamine ou leurs sels et remedes contre les maladies a degenerescence nerveuse, qui les contiennent

Publications (3)

Publication Number Publication Date
HUP0204177A2 true HUP0204177A2 (hu) 2003-03-28
HUP0204177A3 HUP0204177A3 (en) 2007-05-29
HU229250B1 HU229250B1 (en) 2013-10-28

Family

ID=15820725

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204177A HU229250B1 (en) 1999-06-11 2000-06-09 N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same

Country Status (24)

Country Link
US (1) US6797726B1 (hu)
EP (1) EP1186594B1 (hu)
JP (1) JP4782961B2 (hu)
KR (1) KR100641352B1 (hu)
CN (1) CN1155558C (hu)
AT (1) ATE438614T1 (hu)
AU (1) AU770234B2 (hu)
BR (1) BR0011505A (hu)
CA (1) CA2374659C (hu)
CY (1) CY1109334T1 (hu)
CZ (1) CZ302083B6 (hu)
DE (1) DE60042686D1 (hu)
DK (1) DK1186594T3 (hu)
ES (1) ES2329003T3 (hu)
HU (1) HU229250B1 (hu)
MX (1) MXPA01012627A (hu)
NO (1) NO322473B1 (hu)
NZ (1) NZ515706A (hu)
PL (1) PL196773B1 (hu)
PT (1) PT1186594E (hu)
RO (1) RO122361B1 (hu)
SK (1) SK287673B6 (hu)
WO (1) WO2000076957A1 (hu)
ZA (1) ZA200109699B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100956990B1 (ko) 2001-10-19 2010-05-11 토야마 케미칼 컴퍼니 리미티드 알킬에테르유도체 또는 그 염
ES2379948T3 (es) * 2002-06-14 2012-05-07 Toyama Chemical Co., Ltd. Composición medicinal que comprende Tacrine o Donepezil para mejorar la función cerebral
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
JP4902247B2 (ja) * 2005-04-08 2012-03-21 富山化学工業株式会社 ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体
JP2006328058A (ja) * 2005-04-27 2006-12-07 Toyama Chem Co Ltd ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
PL2011796T3 (pl) * 2006-04-26 2015-03-31 Toyama Chemical Co Ltd Induktor neurogenezy lub środek terapeutyczny do stosowania w neuropatii zawierający pochodną eteru alkilowego lub jej sól
FR2933977B1 (fr) * 2008-07-18 2013-04-26 Centre Nat Rech Scient Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) * 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
US5280032A (en) 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP2887492B2 (ja) * 1990-02-05 1999-04-26 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JP3044055B2 (ja) * 1990-08-09 2000-05-22 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JP2873898B2 (ja) * 1992-04-13 1999-03-24 富山化学工業株式会社 ベンゾ［ｂ］チオフェン−５−イル誘導体もしくはその光学活性体またはそれらの塩並びにそれらの製造法
WO1995019336A1 (de) * 1994-01-12 1995-07-20 Iovis Biomedical And Pharmaceutical Consultants Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten
EP0790246B1 (en) * 1994-10-25 2002-01-16 Toyama Chemical Co., Ltd. Potentiator for nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
WO1999031056A1 (fr) 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant

Also Published As

Publication number Publication date
SK287673B6 (sk) 2011-05-06
NO20016029L (no) 2001-12-10
ATE438614T1 (de) 2009-08-15
RO122361B1 (ro) 2009-04-30
EP1186594A4 (en) 2006-01-11
AU5107200A (en) 2001-01-02
KR100641352B1 (ko) 2006-11-02
EP1186594B1 (en) 2009-08-05
ES2329003T3 (es) 2009-11-20
ZA200109699B (en) 2003-03-12
DE60042686D1 (de) 2009-09-17
AU770234B2 (en) 2004-02-19
CA2374659C (en) 2010-07-13
HU229250B1 (en) 2013-10-28
WO2000076957A1 (fr) 2000-12-21
DK1186594T3 (da) 2009-09-14
JP4782961B2 (ja) 2011-09-28
SK17812001A3 (sk) 2002-11-06
PL352172A1 (en) 2003-07-28
NO20016029D0 (no) 2001-12-10
MXPA01012627A (es) 2003-09-04
NO322473B1 (no) 2006-10-09
CY1109334T1 (el) 2014-07-02
PL196773B1 (pl) 2008-01-31
HUP0204177A3 (en) 2007-05-29
PT1186594E (pt) 2009-10-13
CN1358169A (zh) 2002-07-10
EP1186594A1 (en) 2002-03-13
KR20020013902A (ko) 2002-02-21
CN1155558C (zh) 2004-06-30
NZ515706A (en) 2003-08-29
US6797726B1 (en) 2004-09-28
CZ302083B6 (cs) 2010-09-29
CA2374659A1 (en) 2000-12-21
BR0011505A (pt) 2002-08-20

Similar Documents

Publication Publication Date Title
HUP0301722A2 (hu) Pirimidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301005A2 (hu) Pirrolotriazin kináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MX2021009854A (es) Compuesto derivado heterociclico novedoso y uso del mismo.
HUP0500017A2 (hu) Alkil-éter-származékok, sóik és az ezeket tartalmazó gyógyszerkészítmények
TR199901259T2 (xx) Nos inhibit�rleri olarak fayda ta��yan 6-fenilpiridil-2-amin t�revleri
HUP0401481A2 (hu) Kinolinszármazékok, mint neuropeptid Y antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0302337A2 (hu) Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9802426A2 (hu) 2,4-Diamino-1,3,5-triazin-származékok, eljárás előállításukra és ezeket tartalmazó herbicid és növekedésszabályozó készítmények
HUP0103366A2 (hu) Citokin inhibítorként használható amidszármazékok
HUP9901016A2 (hu) 4-Kinolinkarboxamid-származékok, előállításuk, valamint neurokinin-3 (NK-3) és neurokinin-2 (NK-2) receptor antagonistákként történő felhasználásuk
HUP0301187A2 (hu) Új benzil-piperidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0104959A2 (hu) 4-Kinolinkarboxamid-származékok, előállításuk, neurokinin-2 (NK-2) és neurokinin-3 (NK-3) receptor antagonistákként történő felhasználásuk, valamint a vegyületeket tartalmazó gyógyszerkészítmények
HUP0000496A2 (hu) Heterociklusos csoporttal szubsztituált benzamidszármazékok és alkalmazásuk betegségek leküzdésére
HUP0203054A2 (hu) Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
HUP0204177A2 (hu) N-(Alkoxi-alkil)-N,N-dialkil-aminszármazékok vagy sóik és ezeket tartalmazó szerek neurodegeneratív betegségek kezelésére
DE69313051T2 (de) Ethanolamin-derivate mit sympathomimetischer und anti-pollakiuria wirkung
ZA984637B (en) Spiro-quinuclidine derivatives their preparation and use
CY1124346T1 (el) ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ
BR0316206A (pt) Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
ES512574A0 (es) "procedimiento de preparacion de derivados carboxilato".
ES2196332T3 (es) Derivados de hexahidro-pirido(4,3-b)indol como farmacos antipsicoticos.
HUP0400344A2 (hu) Új heteroarilszármazékok, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees